RT Journal Article
T1 Risk factors and outcome of COVID-19 in patients with hematological malignancies
A1 Piñana, José Luis
A1 Martino, Rodrigo
A1 García-García, Irene
A1 Parody, Rocío
A1 Morales, María Dolores
A1 Benzo, Gonzalo
A1 Gómez-Catalan, Irene
A1 Coll, Rosa
A1 De La Fuente, Ignacio
A1 Luna, Alejandro
A1 Merchán, Beatriz
A1 Chinea, Anabelle
A1 de Miguel, Dunia
A1 Serrano, Ana
A1 Pérez, Carmen
A1 Diaz, Carola
A1 Lopez, José Luis
A1 Jesús Saez, Adolfo
A1 Bailen, Rebeca
A1 Zudaire, Teresa
A1 Martínez, Diana
A1 Jurado, Manuel
A1 Calbacho, María
A1 Vázquez, Lourdes
A1 Garcia-Cadenas, Irene
A1 Fox, Laura
A1 Pimentel, Ana I
A1 Bautista, Guiomar
A1 Nieto, Agustin
A1 Fernandez, Pascual
A1 Vallejo, Juan Carlos
A1 Solano, Carlos
A1 Valero, Marta
A1 Espigado, Ildefonso
A1 Saldaña, Raquel
A1 Sisinni, Luisa
A1 Ribera, Josep Maria
A1 Jimenez, Maria Jose
A1 Trabazo, Maria
A1 Gonzalez-Vicent, Marta
A1 Fernández, Noemí
A1 Talarn, Carme
A1 Montoya, Maria Carmen
A1 Cedillo, Angel
A1 Sureda, Anna
K1 Risk factor
K1 Hematologic neoplasms
K1 COVID-19
K1 Coronavirus infections
K1 Multicenter study
K1 Retrospective studies
K1 Polymerase chain reaction
K1 Stem cell transplantation
K1 SARS-CoV-2
K1 Mortality
K1 Factores de riesgo
K1 Neoplasias hemtaológicas
K1 Infecciones por coronavirus
K1 Estudio multicéntrico
K1 Estudio restrospectivo
K1 Reacción en cadena de la polimerasa
K1 Trasplante de células madre
K1 Mortalidad
AB Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined.Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020.Results: We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1-93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2-3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6-5.2, p < 0.0001); ECOG 3-4 (OR, 2.56, 95% CI 1.4-4.7, p = 0.003); neutropenia (< 0.5 × 109/L) (OR 2.8, 95% CI 1.3-6.1, p = 0.01); and a C-reactive protein (CRP) > 20 mg/dL (OR 3.3, 95% CI 1.7-6.4, p < 0.0001). In multivariate analysis of 216 patients with very severe COVID-19, treatment with azithromycin or low dose corticosteroids was associated with lower OM (OR 0.42, 95% CI 0.2-0.89 and OR 0.31, 95% CI 0.11-0.87, respectively, p = 0.02) whereas the use of hidroxycloroquine did not show significant improvement in OM (OR 0.64, 95% CI 0.37-1.1, P = 0.1).Conclusions: In most patients with hematological malignancies COVID-19 mortality was directly driven by older age, disease status, performance status, as well as by immune (neutropenia) parameters and level of inflammation (high CRP). Use of azithromycin and low dose corticosteroids may be of value in very severe COVID-19.
PB BioMed Central
YR 2020
FD 2020-08-25
LK http://hdl.handle.net/10668/3275
UL http://hdl.handle.net/10668/3275
LA en
NO Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020 Aug 25;9:21.
DS RISalud
RD Apr 6, 2025